| Literature DB >> 35242479 |
Guy Treves1, Mustaqueem Qazi2.
Abstract
This case report details a unique case of fibromyalgia manifested at a very early age, and the patient's suffering as a result of mis- and under-diagnosis of her condition for over a decade. For most of her life, the patient has had seemingly unrelated bouts of pain, neurological conditions, and psychiatric disturbances, and has seen numerous specialists for these conditions to no avail. The lengthy history discussion and physical examination findings, detailed in this report, revealed a progressive disease course. Providing the patient with drafts of the compiled history and data has encouraged her to reseek specialist care. With this revealed history, physical examination information, and lab results, progress has been made to diagnose and treat the patient's numerous conditions. In addition to the unique fibromyalgia presentation, the case report provides compelling justification for physicians to consider broad differential diagnoses, engage in patient-centered discussion about treatment progression, and to strengthen and maintain the patient-provider relationship.Entities:
Keywords: autoimmune; autoimmune pots; early onset fibromyalgia; fibromyalgia; unusual presentation
Year: 2022 PMID: 35242479 PMCID: PMC8884524 DOI: 10.7759/cureus.21714
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Laboratory values
*Abnormal values.
SGU: specific gravity units; EU: endotoxin units
| Comprehensive metabolic panel | Reference | |
| Glucose | 80 | 65-99 mg/dL |
| Blood urea nitrogen (BUN) | 12 | 7-20 mg/dL |
| Creatinine | 0.73 | 0.50-1.00 mg/dL |
| Estimated glomerular filtration rate non-African American | 119 | > or = 60 mL/min/1.73m2 |
| Estimated glomerular filtration rate African American | 138 | > or = 60 mL/min/1.73m2 |
| BUN/creatinine ratio | Not applicable | 6-22 (calculated) |
| Sodium | 138 | 135-146 mmol/L |
| Potassium | 4.2 | 3.8-5.1 mmol/L |
| Chloride | 102 | 98-110 mmol/L |
| Carbon dioxide | 19 L* | 20-32 mmol/L |
| Calcium | 9.8 | 8.9-10.4 mg/dL |
| Total protein | 7.5 | 6.3-8.2 g/dL |
| Albumin | 4.5 | 3.6-5.1 g/dL |
| Globulin | 3.0 | 2.0-3.8 g/dL (calculated) |
| Albumin/globulin ratio | 1.5 | 1.0-2.5 (calc) |
| Total bilirubin | 0.6 | 0.2-1.1 mg/dL |
| Alkaline phosphatase | 56 | 36-128 U/L |
| Aspartate aminotransferase | 18 | 12-32 U/L |
| Alanine aminotransferase | 18 | 5-32 U/L |
| Erythrocyte sedimentation rate by modified Westergren | 17 | < or = 20 mm/h |
| Aldolase | 3.7 | < or = 8.1 U/L |
| Vitamin B12 | 312 | 200-1100 pg/mL |
| Folate | 572 | >280 ng/mL red blood cells |
| Total creatine kinase | 77 | 29-143 U/L |
| Total vitamin D 1,25 (OH)2 | 68 | 18-72 pg/mL |
| Vitamin D3, 1,25 (OH)2 | 68 | 18-72 pg/mL |
| Vitamin D2, 1,25 (OH)2 | <8 | 18-72 pg/mL |
| Thrombin clotting time | 16 | 13-19 seconds |
| Complete blood count | ||
| White blood cell count | 8.3 | 3.8-10.8 thousand/uL |
| Red blood cell count | 4.37 | 3.80-5.10 million/uL |
| Hemoglobin | 13.7 | 11.7-15.5 g/dL |
| Hematocrit | 40.0 | 35.0-45.0% |
| Mean corpuscular volume | 91.5 | 80.0-100.0 fL |
| Mean corpuscular hemoglobin | 31.4 | 27.0-33.0 pg |
| Mean corpuscular hemoglobin concentration | 34.3 | 32.0-36.0 g/dL |
| Red cell distribution width | 12.0 | 11.0-15.0% |
| Platelet count | 376 | 140-400 thousand/uL |
| Mean platelet volume | 9.9 | 7.5-12.5 fL |
| Absolute neutrophils | 5279 | 1500-7800 cells/uL |
| Absolute lymphocytes | 2357 | 850-3900 cells/uL |
| Absolute monocytes | 515 | 200-950 cells/uL |
| Absolute eosinophils | 100 | 15-500 cells/uL |
| Absolute basophils | 50 | 0-200 cells/uL |
| Absolute nucleated red blood cells | 0 | 0 cells/uL |
| Neutrophils | 63.6 | % |
| Lymphocytes | 28.4 | % |
| Monocytes | 6.2 | % |
| Eosinophils | 1.2 | % |
| Basophils | 0.6 | % |
| Antibodies titer and pattern | ||
| Human leukocyte antigen B27 | Negative | Negative |
| Antinuclear antibodies screen with immunofluorescence assay | Positive* | Negative |
| Antinuclear antibodies titer | 1:80 H* | 40 titer |
| Antinuclear antibodies pattern | Nuclear, homogeneous* | |
| Thyroglobulin antibodies | <1 | < or = 1 IU/mL |
| Complement component C3C | 133 | 83-193 mg/dL |
| Complement component C4C | 38 | 15-57 mg/dL |
| Total complement (CH50) | >60 H* | 31-60 U/mL |
| Rheumatoid factor | <14 | <14 IU/mL |
| C-reactive protein | 2.0 | <8.0 mg/L |
| SCL-70 antibody | <1.0 negative | <1.0 negative |
| Thyroid peroxidase antibodies | 96 H* | <9 IU/mL |
| Thyroid-stimulating hormone antibody | Negative | Negative |
| Sjogren's antibody (SS-A) | <1.0 negative | <1.0 negative |
| Sjogren's antibody (SS-B) | <1.0 negative | <1.0 negative |
| Cyclic citrullinated peptide antibodies (IgG) | <16 | 19 units |
| Centromere B antibody | <1.0 negative | <1.0 negative |
| Ribonucleoprotein antibody | <1.0 negative | <1.0 negative |
| Anti-Smith antibody | <1.0 negative | <1.0 negative |
| Total hepatitis B core antibody | Non-reactive | Non-reactive |
| Hepatitis B core antibody (IgM) | Non-reactive | Non-reactive |
| Hepatitis C antibody | Non-reactive | Non-reactive |
| Lupus anticoagulant | Detected* | Not detected |
| Partial thromboplastin time - lupus anticoagulant screen | 48 H* | < or = 40 seconds |
| Dilute Russell viper venom time screen | 46 H* | < or = 45 seconds |
| Hexagonal phase confirm | Weakly positive* | Negative |
| Dilute Russell viper venom time confirm | Positive* | Negative |
| 1:1 mix dilute Russell viper venom time | Corrected | Corrected |
| DNA double-stranded antibodies by Crithidia luciliae (IFA) | Negative | Negative |
| Salivary protein (SP 1) IgG antibodies | 4.0 | <19.9 EU/mL |
| Salivary protein (SP 1) IgA antibodies | <1.0 | <19.9 EU/mL |
| Salivary protein (SP 1) IgM antibodies | <1.0 | <19.9 EU/mL |
| B2 glycoprotein IgG antibodies | <9 | ≤ 20 SGU |
| B2 glycoprotein IgM antibodies | <9 | ≤ 20 SGU |
| B2 glycoprotein IgA antibodies | <9 | ≤ 20 SGU |
| Carbonic anhydrase VI (CA VI) IgG antibodies | 21.6 H* | <19.9 EU/mL |
| Carbonic anhydrase VI (CA VI) IgA antibodies | 1.4 | <19.9 EU/mL |
| Carbonic anhydrase VI (CA VI) IgM antibodies | <1.0 | <19.9 EU/mL |
| Parotid specific protein (PSP) IgG antibodies | 2.4 | <19.9 EU/mL |
| Parotid specific protein (PSP) IgA antibodies | <1.0 | <19.9 EU/mL |
| Parotid specific protein (PSP) IgM antibodies | <1.0 | <19.9 EU/mL |
| 14.3.3η (eta) protein | <0.2 | <0.2 ng/mL |
| Cardiolipin antibody (IgA) | <11 | IgA isotype |
| Cardiolipin antibody (IgG) | <14 | IgG isotype |
| Cardiolipin antibody (IgM) | <12 | IgM isotype |
Medications and allergies
| Current medications | Side effects |
| Seasonique | - |
| Cymbalta 30mg twice daily | - |
| Gabapentin 300mg thrice daily, weaning | Sleepiness, loss of appetite |
| Magnesium 250mg twice daily | - |
| Fish oil | - |
| Vitamin D 35 mcg daily | - |
| Zofran as needed for nausea | - |
| Previous medications | |
| Lexapro | Did not do enough for depression, anxiety, obsessive-compulsive disorder |
| Piroxicam | Appetite loss, nausea |
| Enskyce | Severe reaction including intense vomiting leading to emergency room visit |
| LoSeasonique | No effect |
| Norco | Prescribed at emergency room, very helpful with pain |
| Flexeril | Prescribed at emergency room, effective relaxant but causes excessive tiredness |
| Meclizine | Extreme dizziness |
| Zoloft | Switched to Cymbalta due to nerve pain |
| Allergies | |
| Sensitive skin to soaps and chlorine | Can tolerate gentle soaps |
| Bee allergy/sensitivity | Patient has an EpiPen but never used |
| Piroxicam | Nausea and loss of appetite |
| Enskyce | Severe reaction including intense vomiting |
Figure 1Diagrammatic representation of pain felt upon palpation